“Mental toughness is doing the right thing for the team when it’s not the best thing for you.”
— Bill Belichick
David Rosenbaum, PhD
Chief Development Officer
David has served as our Chief Development Officer since January 2015 and, before that, served as our vice president of drug development since January 2010. David has more than 30 years of experience developing new therapies for global registration and has focused his efforts on non-absorbed, minimally systemic new chemical entities.
David began his career at Arthur D. Little (ADL), where he was a senior consultant and study director for more than 100 pharmacology and GLP toxicology studies in a wide variety of therapeutic areas. Since ADL, David has spent his career working for start-up and small pharmaceutical companies. Notably, David was vice president of preclinical research and development at GelTex Pharmaceuticals, where he was integral in the development and approval of two non-absorbed drugs: Renvela® (sevelamer and WelChol). Most recently, David was vice president of drug development for Trine Pharmaceuticals, where he was developing a novel non-systemic therapeutic for the treatment of Irritable Bowel Syndrome. David has filed numerous Investigational New Drug (IND) applications, met with regulatory agencies around the world, and filed four approved New Drug Applications (NDA).
David earned a Bachelor of Arts in biology from the University of Pennsylvania, a Master of Science in toxicology from Albany Medical College, and a doctoral degree in pharmacology from Boston University School of Medicine.
“Mental toughness is doing the right thing for the team when it’s not the best thing for you.”
— Bill Belichick